




# 2019 ANNUAL REPORT



ICCBBA, the international standards organization responsible for the management and development of the ISBT 128 Standard, is a not-for-profit nongovernmental organization in official relations with the World Health Organization (WHO).



# ICCBBA Vision, Mission, & Priorities



## MISSION

Global adoption of ISBT 128 for all medical products of human origin.



## VISION

Enhancing patient safety by promoting and managing the ISBT 128 international information standard for use with medical products of human origin.



## PRIORITIES

1

To manage international information standards for transfusion medicine, transplantation, and other applications of medical products of human origin in support of traceability, biovigilance, and patient safety.

2

To liaise with health authorities, regulators, scientific and professional societies, user communities, and vendors on standardization in terminology and information technology.

3

To provide educational programs to promote the value of, and need for, information standards and policies to support traceability and biovigilance.

4

To provide technical consultation regarding the implementation and management of ISBT 128.

5

To lead in the continued development of common data structures for information technology, data processing, exchange and transfer, and labeling for medical products of human origin.



# ICCBBA Board Members

ICCBBA is governed by a volunteer Board of Directors comprising leading experts in blood transfusion, cellular therapy, and tissue transplantation from around the world. Board positions are advertised publicly and Board members normally serve six year terms. The current Board of Directors has members from Belgium, Germany, India, The Netherlands, Bhutan, the United States, and the United Kingdom.



**Diane Wilson**  
United States



**Timothy L. Pruett**  
United States



**Martin Hildebrandt**  
Germany



**Zbigniew M  
Szczepiorkowski**  
United States



**John Armitage**  
United Kingdom



**Mahrukh Getshen**  
Bhutan



**Ineke Slaper-Cortenbach**  
The Netherlands



**Joy Mammen**  
India



**Kelly Tilleman**  
Belgium

The governance role of the Board ensures that ICCBBA is managed in an effective and efficient manner and is appropriately staffed and funded whilst at the same time ensuring a fee structure that is fair and appropriate. As Board Members receive no remuneration, and have no long term association with ICCBBA they can maintain the necessary balance and independence to ensure stakeholders receive good value for money.


In this way the ICCBBA Board of Directors has ensured that ICCBBA has developed in a sustainable and responsible manner since its creation in 1994, and will continue to ensure effective controls and efficiencies as ISBT 128 moves forward as the International Standard for Medical Products of Human Origin.




# Operating Income

In US Dollar

Registration Fees	33,387
License Fees - Facilities	1,298,022
License Fees - Vendors	532,835
Forum 25	4,338
<b>TOTAL</b>	<b>1,868,582</b>



Staff Costs	1,231,323
Scientific Congresses & Exhibitions	90,558
Technical, Development & Board Meetings	164,086
Office Expenses	42,241
Office Rental	93,929
Donations and Awards	11,547
Professional Services	27,034
Communication Services	39,870
Staff Administrative Travel	7,766
Banking Fees	25,595
Insurance	20,964
Forum 25	185,399
<b>TOTAL EXPENDITURE</b>	<b>1,940,309</b>
Net Operating Income	71,727
<b>TOTAL</b>	<b>1,868,582</b>





# 2018 Balance Sheet

In US Dollar

## ASSETS

### Current Assets

Cash	354,290
Interest Receivable	1,533
<b>TOTAL CURRENT ASSETS</b>	<b>355,823</b>

### Equipment

Office Furniture & Equipment	58,850
Computer Hardware & Software	58,246
Less Accumulated Depreciation	101,423
<b>Total Equipment</b>	<b>15,673</b>
Deposits	6,254
Investments	2,974,018

**TOTAL ASSETS: 3,351,768**

## LIABILITES & NET ASSETS

### Current Liabilities

Credit Card Liability	13,335
Other	2,336
Accrued Pension Contributions	27,857
<b>Total Current Liabilities</b>	<b>43,528</b>

### Net Assets - Unrestricted

Undesignated	1,506,122
Designated	1,802,118
<b>Total Net Assets</b>	<b>3,308,240</b>

**TOTAL LIABILITES & NET ASSETS: 3,351,768**



# A HISTORY OF ICCBBA: 1994 - 1995

1994

1995



The United States Department of Defence and Baxter Healthcare in Deerfield, Illinois provide a three year grant to assist in the establishment of the office where ICCBBA will eventually be created.

In November the first full Board of Directors meeting commences. The Americas Technical Advisory Group (ATAG) is established to advise ICCBBA on needs of users in the Americas.

ISBT Council formally cedes ownership of ISBT 128 to ICCBBA, Inc.



ICCBBA, Inc. receives not-for-profit status from the US Internal Revenue Service.

ICCBBA publishes version 1.0.0 of the document "Bar Code Symbology and Application Specification for Labeling of Whole Blood and Blood Components".

AABB and American Red Cross appoint members to form a Board of Directors for new office. The ISBT Council approves the ISBT 128 Standard and agrees in principle to form ICCBBA by adding members to the CoCBBA Board of directors. CoCBBA was the original Council for Commonality in Blood Banking Automation, Inc. a committee established by the AABB, before evolving into ICCBBA.



An Executive Director is selected and an office opens with space rented from AABB. ICCBBA becomes an official entity.



International Council for Commonality in Blood Banking Automation, Inc.

First official meeting of the North America Technical Advisory Group (NATAG, now ATAG).

In February, ICCBBA's Board of Directors meet, writes bylaws, establishes a budget, and prepares Articles of Incorporation for the subsequent incorporation of ICCBBA in the Commonwealth of Virginia.




The Blood Products Advisory Committee of the FDA votes in March of this year to recommend the use of ISBT 128 in the US according to a timetable presented by ICCBBA, Inc.



Registration and license fees are established and the first vendor registers with ICCBBA.



# A HISTORY OF ICCBBA: 1996 - 1998





# A HISTORY OF ICCBBA: 1999 - 2002

ICCBBA publishes the ISBT 128 US Consensus Standard as a guidance document.

Number of registered facilities reaches 1,500.



In the United Kingdom, NHS Blood & Transplant is the first tissue facility that registers with ICCBBA.



## ATTENDING CONGRESSES

On a yearly basis, ICCBBA staff travel to various congresses worldwide to spread awareness of ICCBBA's mission of the global adoption of ISBT 128 for all medical products of human origin.

1999

2000

2001

2002

4,000th Product Description Code added.



MEETAG (EMATAG) MEMBERS IN CAIRO, EGYPT

St. Luke's Episcopal Hospital in Houston, Texas becomes the first facility in the United States to implement ISBT 128 in its blood bank.



# A HISTORY OF ICCBBA: 2003 - 2005

The United Kingdom and Switzerland implement ISBT 128 nationally for blood transfusions.

A facility in Turkey becomes the 100th vendor that registers with ICCBBA.



Kuwait implements ISBT 128 as a national solution in blood banking.



**PROVIDING EDUCATION AND PROMOTION - HONG KONG**



2003

2004

2005

The 5,000th Product Description Code in the category of blood is added.


Mexico becomes 25th country to have registered facilities licensed to use ISBT 128 with ICCBBA.



**ICCBBA BOARD AND STANDARDS COMMITTEE MEETING IN LONG BEACH, CALIFORNIA, USA**




Hospitals in Norway start to use secure wristband identification using ISBT 128 data structures.





# A HISTORY OF ICCBBA: 2006 - 2008





# A HISTORY OF ICCBBA: 2009 - 2011

ICCBBA partners with the International Blood Emergency Planning Action Group (IBEPAG) to carry out a survey that tabulated which blood institutions had implemented or were planning on implementing ISBT 128.

Table of Potential Additive Solutions									
Name	Control	Isophore	Acetate	agitation	Phosphate	Glycerate	Glycerate	Isolate Name	Previous ID#? (Y/N)
PAS-01	SN	SN	SN	SN	SN	SN	SN		not named
PAS-02	XX	XX						PAS-1 (N)	
PAS-03			X					PAS-1, PAS-1, SSP-1, SSP-1	PAS0
PAS-04	XX							PAS-1, PAS-3, internal	
PAS-05								PAS01	
PAS-06		XX		XX				PAS-1 (N), Comp-1 (N)	PAS-1 (N), Comp-1 (N)
PAS-07	XX		XX					PAS-1 (N), SSP-1, SSP-1	Not named
PAS-08						X		Phosphate, X, X, X	Not named
PAS-09	XX	XX	XX	XX			XX		not named

The journal of the ISBT, Vo  
Standard Terminology for Platelet Additive Solutions.

First meeting of the European Tissue Technical Advisory Group (ETTAG) occurs in Krakow, Poland.

# 2009

# 2010

2011

ICCBBA enters into official relations with the World Health Organization.

**DR. CLIVE HOHBERGER: 2011  
ONE WORLD AWARD WINNER**

First year that ICCBBA becomes ISO 9001 certified.

The One World Award is Presented  
to Dr. Charles Munk, its first  
recipient.

The World Health Assembly passes resolution WHA63.22 which urges Member States to encourage the implementation of globally consistent coding systems for human cells, tissues, and organs.

First conference call for the  
Regenerative Medicine Technical  
Advisory Group.

## FIRST ONE WORLD AWARD RECIPIENT: DR. CHARLES MUNK



# A HISTORY OF ICCBBA: 2012 - 2015



5,000th facility registers with ICCBBA.

Dr. Edwin A. Steane is presented with the One World Award. Dr. Steane was previously the first Executive Director of ICCBBA as well as one of the original creators of the ISBT 128 Standard.



**WHO-ICCBBA JOINT WORKSHOP IN ANNECY, FRANCE**

FDA's Center for Devices and Radiologic Health (CDRH) approves ICCBBA as one of only three issuing agencies for medical device Unique Device Identifiers (UDI) in the US.

Gameta Szpital Sp. Z O.o. in Poland becomes the first reproductive facility to register with ICCBBA.

2012

2013

2014


2015

First conference call for Milk Banking Technical Advisory Group (MBTAG).



**ICCBBA CELEBRATES 20th ANNIVERSARY IN 2014**

The European Commission publishes directive that recognizes ISBT 128 to be compatible with the SEC.




ICCBBA releases version 1.0 of the Product Lookup Program.



# A HISTORY OF ICCBBA: 2016 - 2018

Version 1.0 of an implementation guide on blood transfusion for resource limited countries is published. The intended audiences of this document are blood transfusion services and hospital blood banks.

ICCBBA releases version 1.0 of the Product Lookup Program.



Enterobiotix, Ltd. In Scotland becomes the first fecal microbiota facility that registers with ICCBBA.

ICCBBA releases version 1.0 of the Single European Code Builder Tool.

AABB, FACT, JACIE, and NMDP require that ISBT 128 terminology be used when labeling cellular therapy products. AABB Standards for Cellular Therapy requires that all facilities shall implement ISBT 128 labeling by 01 July 2018.


2016

2017

2018

ICCBBA creates the Enterprise Grant aimed at supporting organizations working in resource limited countries that develop initiatives that have an impact on information management or traceability.

 ICCBBA  
Enterprise Grant



The Eye Bank Association of America (EBAA) requires ISBT 128 barcoding for international shipments for eye banks in North America. ICCBBA releases a guidance document (IG-040) in relation to this.

The first Enterprise Grant is awarded to Global Healing, a nonprofit organization based in Berkeley, California, for its proposal to strengthen the quality management system of the blood bank at the Hôpital Universitaire de Mirebalais (HUM) in Haiti.



ICCBBA releases version 1.0 of the Cellular Therapy Audit Tool. The tool is intended for auditors to help them assess compliance to ISBT 128 requirements for cellular therapy products as well as used by facilities wanting to perform a self-assessment or a gap analysis as part of their ISBT 128 implementation efforts.



# A HISTORY OF ICCBBA: 2019



As of September 2019, there exists 15,707 Product Description Codes across all product categories including blood, cellular therapy, ocular tissues, reproductive tissues, regenerative tissues, organs, milk, fecal microbiota, topical, and other products.

As of July 31st 2019, ICCBBA has 5,401 active facilities registered and growing. There are 4,590 Blood, 911 Cell Therapy, 143 Tissue, 119 Ocular, 55 Reproductive, 10 Milk, 5 Medical Device, and 2 Fecal facilities.

## FORUM 25



**ICCBBA host Forum 25 in Lisbon, Portugal to celebrate 25th Anniversary**





**PO Box 11309  
San Bernardino, CA 92423-1309  
United States of America**

**Fax: 1 909 793 6214  
Phone: 1 909 793 6516  
Email: [info@iccbba.org](mailto:info@iccbba.org)**